Background: Although M.S. patients face significant trade-offs between risks and benefits of drug therapy, little is known of their attitudes toward these risks and benefits. Methods: A representative telephone survey of 200 patients with relapsing remitting M.S
Contains fulltext : 172725.PDF (publisher's version ) (Open Access)OBJECTIVES: Und...
Objectives: The aim of this study was to assess pharmacists’ and student pharmacists’ understanding ...
grantor: University of Toronto'Purpose'. Disease-modifying drugs (DMDS) are a recent break...
Background: Although M.S. patients face significant trade-offs between risks and benefits of drug th...
OBJECTIVE: To determine tolerance to various risk scenarios associated with current multiple scleros...
Multiple sclerosis (MS) is a chronic inflammatory demyelinating neurological disorder with no known ...
Background: There are now large cohorts of people with relapsing-remitting multiple sclerosis (pwRRM...
Background: Multiple sclerosis (MS) patients are faced with complex risk-benefit profiles of disease-m...
Jinender Kumar,1 M Janelle Cambron-Mellott,2 Tom Tencer,1 Oliver Will,2 deMauri S Mackie,2 Kathleen ...
BackgroundMultiple sclerosis (MS) patients are faced with complex risk-benefit profiles of disease-m...
Background:Natalizumab is associated with the potentially life-threatening side-effect progressive m...
Background: Poor medication adherence is an ongoing issue, and contributes to increased hospitalizat...
BackgroundTimely individualized treatment is essential to improving relapsing-remitting multiple scl...
Objective: To assess patients' preferences for a range of disease-modifying therapy (DMT) attributes...
Background: Relapses are common in vasculitis and preventing relapses is a goal of treatment and a f...
Contains fulltext : 172725.PDF (publisher's version ) (Open Access)OBJECTIVES: Und...
Objectives: The aim of this study was to assess pharmacists’ and student pharmacists’ understanding ...
grantor: University of Toronto'Purpose'. Disease-modifying drugs (DMDS) are a recent break...
Background: Although M.S. patients face significant trade-offs between risks and benefits of drug th...
OBJECTIVE: To determine tolerance to various risk scenarios associated with current multiple scleros...
Multiple sclerosis (MS) is a chronic inflammatory demyelinating neurological disorder with no known ...
Background: There are now large cohorts of people with relapsing-remitting multiple sclerosis (pwRRM...
Background: Multiple sclerosis (MS) patients are faced with complex risk-benefit profiles of disease-m...
Jinender Kumar,1 M Janelle Cambron-Mellott,2 Tom Tencer,1 Oliver Will,2 deMauri S Mackie,2 Kathleen ...
BackgroundMultiple sclerosis (MS) patients are faced with complex risk-benefit profiles of disease-m...
Background:Natalizumab is associated with the potentially life-threatening side-effect progressive m...
Background: Poor medication adherence is an ongoing issue, and contributes to increased hospitalizat...
BackgroundTimely individualized treatment is essential to improving relapsing-remitting multiple scl...
Objective: To assess patients' preferences for a range of disease-modifying therapy (DMT) attributes...
Background: Relapses are common in vasculitis and preventing relapses is a goal of treatment and a f...
Contains fulltext : 172725.PDF (publisher's version ) (Open Access)OBJECTIVES: Und...
Objectives: The aim of this study was to assess pharmacists’ and student pharmacists’ understanding ...
grantor: University of Toronto'Purpose'. Disease-modifying drugs (DMDS) are a recent break...